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B Cell Tetherin: A Flow Cytometric Cell-Specific Assay for 
Response to Type I Interferon Predicts Clinical Features and 
Flares in Systemic Lupus Erythematosus
Yasser M. El-Sherbiny,1  Md Yuzaiful Md Yusof,2  Antonios Psarras,2 Elizabeth M. A. Hensor,2   
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Objective. Type I interferon (IFN) responses are broadly associated with autoimmune diseases, including system-
ic lupus erythematosus (SLE). Given the cardinal role of autoantibodies in SLE, this study was undertaken to investi-
gate whether the findings of a B cell–specific IFN assay correlate with SLE activity.
Methods. B cells and peripheral blood mononuclear cells (PBMCs) were stimulated with type I IFN and type II IFN. 
Gene expression was analyzed, and the expression of pathway- related membrane proteins was determined. A flow 
cytometry assay for tetherin (CD317), an IFN- induced protein ubiquitously expressed on leukocytes, was validated 
in vitro and then clinically against SLE diagnosis, plasmablast expansion, and the British Isles Lupus Assessment 
Group (BILAG) 2004 score in a discovery cohort (n = 156 SLE patients, 30 rheumatoid arthritis [RA] patients, and 25 
healthy controls). A second, longitudinal validation cohort of 80 SLE patients was also evaluated for flare prediction.
Results. In vitro, a close cell- specific and dose- response relationship between type I IFN–responsive genes and 
cell surface tetherin was observed in all immune cell subsets. Tetherin expression on multiple cell subsets was selec-
tively responsive to stimulation with type I IFN compared to types II and III IFNs. In patient samples from the discov-
ery cohort, memory B cell tetherin showed the strongest associations with diagnosis (SLE:healthy control effect size 
0.11 [P = 0.003]; SLE:RA effect size 0.17 [P < 0.001]), plasmablast numbers in rituximab- treated patients (R = 0.38, 
P = 0.047), and BILAG 2004. These associations were equivalent to or stronger than those for IFN score or monocyte 
tetherin. Memory B cell tetherin was found to be predictive of future clinical flares in the validation cohort (hazard ratio 
2.29 [95% confidence interval 1.01–4.64]; P = 0.022).
Conclusion. Our findings indicate that memory B cell surface tetherin, a B cell–specific IFN assay, is associated 
with SLE diagnosis and disease activity, and predicts flares better than tetherin on other cell subsets or whole blood 
assays, as determined in an independent validation cohort.
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INTRODUCTION
Type I interferons (IFNs) are a highly pleiotropic group of 
cytokines that link the innate and adaptive immune systems and 
play a pivotal role in autoimmune disease (1–3). All nucleated cells 
express type I IFN receptors and express a set of IFN- stimulated 
genes (ISGs) after exposure to type I IFN (4,5). Hundreds of 
effects of type I IFN on various cellular processes, interactions, 
and  disease processes have been described. A challenge in the 
assessment of type I IFN response in an individual disease is 
therefore ensuring that the appropriate cellular response can be 
detected within this complex system.
Type I IFN proteins are unstable in blood and not easily 
detected even in monogenic interferonopathies with known high 
type I IFN production, possibly due to their efficient binding to 
the abundant IFN receptor (6). Type I IFN activity is therefore 
usually measured using the expression of ISGs in whole blood. 
We previously analyzed ISG expression in sorted cells from 
patients with systemic lupus erythematosus (SLE), a prototypic 
IFN- mediated disease, and healthy individuals and showed that 
in both groups, ISG expression was markedly higher in mono-
cytes than in other circulating immune cells. ISG expression in 
monocytes therefore dominates ISG assays that use unsorted 
blood (7).
These differing levels of ISG expression in different cell pop-
ulations may be due to the rate of turnover in each population, 
their trafficking to sites of higher type I IFN production in inflamed 
tissues, or priming for type I IFN response by other inflammatory 
mediators. In autoimmunity, type I IFN assays may have value to 
predict flares and response to a range of different targeted thera-
pies (8). However, existing whole blood IFN biomarkers show poor 
or uncertain correlation with disease activity (9–11).
The measurement of type I IFN using ISG expression in whole 
blood has 2 key weaknesses with regard to interpreting pathogenic 
processes. First, changes in expression may reflect the expansion 
or contraction of certain circulating leukocyte populations (12,13) 
that differ in their level of ISG expression. This characteristically 
occurs in inflammatory diseases. In the case of SLE, lymphopenia 
is almost universally seen (14). So, any difference in whole blood 
gene expression may not necessarily indicate a change in the pro-
duction of or exposure to type I IFN. Second, analyzing whole 
blood ISG expression does not allow the detection of key patho-
genic processes among the noise of other, less relevant, effects of 
type I IFN on biology. For example, B cells are a key mediator in 
SLE (15,16). Type I IFN stimulates B cells to differentiate into plas-
mablasts, which are expanded in SLE and correlate with disease 
activity (17,18). We previously demonstrated that the rate of plas-
mablast regeneration after rituximab treatment predicts clinical 
outcome (19). We also previously showed that type I IFN imprints 
plasma cells for the secretion of the proinflammatory molecule 
ISG- 15 (17). Assessment of type I IFN activity in unsorted blood 
gives limited information about the degree to which B cells have 
specifically been stimulated by type I IFN. Further, gene expres-
sion assays do not prove that a phenotypic change in target cells 
has occurred—there has been no widely used biomarker for IFN 
response at the protein level. This may be one reason why some 
patients classified as having a low IFN signature have responded 
well to IFN- blocking therapy (20).
In order to resolve these problems, we developed a flow 
cytometry assay that allows measurement of type I IFN response in 
individual cells without the need for cell sorting. We measured the 
expression of tetherin (also known as bone marrow stromal antigen 
2 [BST- 2]; CD317), a glycosyl phosphatidylinositol–anchored pro-
tein with a unique topology that is ubiquitously expressed on the 
surface of nucleated cells. This molecule is prominent in viral immu-
nology and encoded by a commonly measured ISG expressed 
in all leukocytes (4,5,21–23). Unlike most ISGs, BST2 encodes a 
cell surface protein and can be easily measured in patient sam-
ples by flow cytometry. Sialic acid–binding Ig- like lectin 1 (Siglec- 1) 
is another flow cytometry type I IFN biomarker that has been 
described previously (24,25). However, Siglec- 1 is only expressed 
on monocytes so resolves the issue of changes in the size of cell 
populations but does not allow interrogation of type I IFN responses 
in individual cells subsets, including the key B cell populations that 
are strongly linked to clinical and experimental disease (26–28).
We hypothesized that a dominant pathogenic role of type I 
IFN in SLE is its effect on B cells, promoting plasmablast differen-
tiation and clinical disease. Our reasons for addressing B cells as 
a particular cell of interest in SLE were: 1) SLE is associated with 
autoantibodies, which are made by B cells; 2) there are a num-
ber of susceptibility loci for SLE in genes with important roles in B 
cell signaling and function, such as LYN, BLK, BANK1, PTPN22, 
TNFAIP3, and TNIP1 (29); and 3) the only targeted therapy licensed 
for SLE targets B cells specifically. Using in vitro stimulation and 
sorted cells from SLE patients and healthy individuals, we showed 
that tetherin accurately captures cell- specific responses to type I 
IFN. A crucial issue in biomarker research is demonstrating that 
biomarkers are predictive, correlate with a range of outcomes, and 
can be reproduced in validation studies. In our study, longitudinal 
analysis of discovery and validation cohorts showed that memory 
B cell tetherin levels more accurately correlated with plasmablast 
expansion and clinical features of disease, and predicted flares bet-
ter, compared to monocyte tetherin or whole blood ISG expression.
PATIENTS AND METHODS
The discovery cohort included 156 consecutive SLE pa-
tients, 25 age- matched healthy controls, and 30 patients with 
active rheumatoid arthritis (RA) as non- SLE inflammatory disease 
controls. The RA patients were positive for anti–citrullinated pro-
tein antibody, negative for antinuclear antibody (ANA), and had a 
mean Disease Activity Score in 28 joints of 3.9 (95% confidence 
interval [95% CI] 3.23–4.56). An independent validation cohort 
consisted of 80 SLE patients recruited and studied longitudinally 
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(n = 236 SLE patients total). SLE disease activity was assessed 
at the time of sampling using the British Isles Lupus Assessment 
Group 2004 (BILAG 2004) score (30). Patients in the validation 
cohort were also followed up for subsequent flare (a BILAG score 
of A or B). SLE patient demographics and disease activity are 
shown in Supplementary Table 1, available on the Arthritis & Rheu-
matology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41187/ abstract. Patients with acute or chronic viral infection at 
the time of blood sampling were excluded from this study.
All individuals provided informed written consent, and the 
study was carried out in compliance with the Declaration of 
 Helsinki. The patient blood samples used for this study were 
Figure 1. Tetherin is a scalable cell- specific measure of type I interferon (IFN) response. A, Gating strategy for flow cytometric assessment of tetherin 
on immune cell subsets. A representative flow cytometry plot of tetherin protein expression on individual immune cell subsets is shown. FSC- A and 
SSC- A were used to define lymphocytes and monocytes. B cells were defined as CD19+ lymphocytes and subdivided into naive, memory, and 
plasmablast subsets using CD27 and CD38. T cells were defined as CD3+, and natural killer (NK) cells were defined as CD3–CD56+ lymphocytes. 
The mean fluorescence intensity (MFI) of bone marrow stromal antigen 2/tetherin for each cell subset compared to isotype control is shown. B, 
Correlation of tetherin protein level with BST2 gene expression for the indicated immune cell subsets. In order to validate tetherin as a cell- specific 
marker, tetherin protein expression was compared with expression of its gene BST2 in various immune cell subsets in systemic lupus erythematosus 
patients and healthy controls. Cell surface tetherin protein levels were determined in unsorted peripheral blood mononuclear cells (PBMCs) by flow 
cytometry, and BST2 gene expression data were determined by quantitative polymerase chain reaction of cells sorted by fluorescence- activated 
cell sorting. There was a strong correlation between gene expression and protein level within each subset, allowing differences in IFN- stimulated 
gene expression between cell subsets to be measured without cell sorting (for monocytes, R = 0.47, P = 0.064; for T cells, R = 0.61, P = 0.012; 
for NK cells, R = 0.63, P = 0.008; for naive B cells, R = 0.63, P = 0.009; for memory B cells, R = 0.78, P = 0.001; and for plasmablasts, R = 0.58, 
P = 0.018). C, Dose- dependent response of memory B cell tetherin and monocyte tetherin to IFN. Healthy control PBMCs (n = 3 samples) were 
stimulated with increasing doses of IFNα, IFNβ, IFNγ, and IFNλ, and tetherin MFI was determined by flow cytometry. D, Tetherin protein levels and 
BST2 gene expression levels in sorted B cells stimulated in vitro with increasing doses of IFNα and evaluated by flow cytometry. There was a parallel 
increase in each marker. Dotted line indicates a 1-fold increase in BST2 gene expression. In C and D, values are the mean ± SD.
EL-­SHERBINY­ET­AL­772       |
obtained with ethics approval (REC 10/H1306/88, National 
Research Ethics Committee Yorkshire and Humber–Leeds 
East), and healthy control participant peripheral blood samples 
were obtained under study number 04/Q1206/107. All exper-
iments were performed in accordance with relevant guidelines 
and regulations. The University of Leeds was contracted with 
administrative sponsorship. Additional details are included in 
the Supplementary Methods, available on the Arthritis & Rheu-
matology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41187/ abstract, and in a previously published methodology 
article (7).
RESULTS
BST-2/tetherin as a cell- specific phenotypic biomarker 
of type I IFN response. Global gene expression profiles have 
shown that many ISGs are responsive to both IFNα and IFNγ, 
while other ISGs respond specifically to IFNα (7,17). We there-
fore tested the effect of IFNα (type I IFN) and IFNγ (type II IFN) 
on 31 of the most commonly reported ISGs. TaqMan quantitative 
polymerase chain reaction (qPCR) analysis of B cells in vitro was 
performed as previously described (17) (Supplementary Figure 1, 
available on the Arthritis & Rheumatology web site at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41187/ abstract). In vitro stimula-
tion confirmed that BST2 was in the group of ISGs predominantly 
responsive to type I IFN.
For this reason, we used multiparameter flow cytometry to 
detect and quantify tetherin on peripheral blood mononuclear cells 
(PBMCs), as described in the Supplementary Methods (available 
on the Arthritis & Rheumatology web site at http://onlin elibr ary.
wiley.com/doi/10.1002/art.41187/ abstract). We used a gating 
strategy that allowed us to define T cells, natural killer (NK) cells, 
and monocytes as well as the B cell subsets naive B cells, memory 
B cells, and plasmablasts. For each of these populations, the mean 
fluorescence intensity (MFI) of tetherin compared to isotype control 
was determined (Figure  1A). We compared cell surface tetherin 
protein levels, determined by flow cytometry, with BST2 gene 
expression, determined by qPCR, for these 6 cell subsets sorted 
by fluorescence- activated cell sorting from 10 SLE patients and 6 
healthy controls. BST2 gene expression levels were substantially 
positively correlated with cell surface tetherin protein levels within 
each of the subsets (Figure 1B). These data confirm that varying 
levels of tetherin/BST2 expression between cell subsets and differ-
ences between individuals may be captured using flow cytometry 
without the need for cell sorting. Furthermore, we compared teth-
erin and Siglec- 1 MFI on monocytes, B cells, and T cells in samples 
from 25 SLE patients and 5 healthy controls. We confirmed that 
tetherin correlated with Siglec- 1 on monocytes only because other 
cell subsets lacked Siglec- 1 expression (Supplementary  Figure 2, 
available on the Arthritis & Rheumatology web site at http://onlin e 
libr ary.wiley.com/doi/10.1002/art.41187/ abstract).
Dose response of tetherin to type I IFN, type II IFN, 
and type III IFN. We tested the dose- response relationship of 
tetherin to IFNα, IFNβ (both type I IFN), IFNγ (type II IFN), and IFNλ 
(type III IFN) on all circulating cell subsets. Healthy control PBMCs 
were stimulated for 48 hours with doses of 0.1–1,000 ng/ml 
and then analyzed by flow cytometry. Interestingly, memory B cell 
Table 1. Tetherin levels in cell subsets in SLE patients and healthy controls*
Mean MFI 
tetherin protein 
levels in SLE 
patients 
(n = 113)†
Within SLE, between  
cell subset
Mean MFI 
tetherin protein 
levels in  
healthy controls 
(n = 17)†
Between group 
(SLE:healthy controls)
Between group, between 
cell subset 
Ratio (90% CI) P Ratio (90% CI) P Ratio (90% CI) P
All subjects
Monocytes 3,388 Reference 2,837 1.19 (0.91–1.58) 0.293 Reference
T cells 687 0.20 (0.19–0.22) <0.001 475 1.45 (1.17–1.79) 0.005 1.21 (1.00–1.46) 0.092
NK cells 1,129 0.33 (0.31–0.36) <0.001 824 1.37 (1.09–1.72) 0.024 1.15 (0.94–1.40) 0.258
Naive B cells 1,118 0.33 (0.30–0.36) <0.001 712 1.57 (1.22–2.03) 0.004 1.32 (1.03–1.68) 0.062
Memory B cells 1,586 0.47 (0.43–0.50) <0.001 1,033 1.53 (1.23–1.92) 0.002 1.29 (1.04–1.58) 0.046
Plasmablasts 2,650 0.78 (0.72–0.84) <0.001 1,813 1.46 (1.15–1.86) 0.009 1.22 (0.99–1.51) 0.115
Rituximab- naive  
 only‡
Monocytes 3,206 Reference 2,949 1.09 (0.80–1.48) 0.657 Reference
T cells 666 0.21 (0.19–0.23) <0.001 494 1.35 (1.07–1.70) 0.034 1.24 (1.01–1.52) 0.080
NK cells 1,068 0.33 (0.31–0.36) <0.001 857 1.25 (0.98–1.58) 0.129 1.15 (0.93–1.41) 0.271
Naive B cells 1,132 0.35 (0.32–0.39) <0.001 740 1.53 (1.20–1.95) 0.004 1.41 (1.15–1.73) 0.006
Memory B cells 1,574 0.49 (0.45–0.53) <0.001 1,074 1.47 (1.17–1.83) 0.005 1.35 (1.11–1.64) 0.013
Plasmablasts 2,597 0.81 (0.74–0.89) <0.001 1,885 1.38 (1.08–1.76) 0.033 1.27 (1.02–1.57) 0.068
* Tetherin cell protein data were natural log–transformed prior to analysis. The back- transformed results represent the ratio of the value for 
each cell subset relative to the value for monocytes within the group of patients with systemic lupus erythematosus (SLE), and the ratio of the 
value for each cell subset in SLE patients relative to that in healthy controls. Interaction ratios (between group, between cell subset) are the ratio 
of the extent of the difference in the value for each cell subset relative to monocytes between SLE patients and healthy controls. MFI = mean 
fluorescence intensity; 90% CI = 90% confidence interval; NK = natural killer. 
† Adjusted for age. 
‡ n = 76 patients with SLE. 
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tetherin MFI was most responsive to increasing doses of IFNα 
and IFNβ, and showed more modest responses to IFNγ and 
IFNλ. Although monocytes had the highest expression of tetherin 
in patient samples and the highest basal expression in unstim-
ulated healthy control PBMCs, they showed much lower fold 
change in tetherin response to type I IFN stimulation (Figure 1C). 
Furthermore, purified B cell response curves for BST2 gene 
expression and tetherin protein MFI revealed a closely matched 
dose- response to IFNα (Figure 1D). We concluded that tetherin 
MFI determined by flow cytometry could accurately measure 
change in the expression of BST2 in response to type I IFN and 
could be used to capture type I IFN exposure in a dose- and cell- 
specific manner.
B cell surface tetherin protein levels best demon-
strate disease- associated IFN response in SLE. We next 
compared tetherin protein expression in immune cell subsets in 
SLE patients and healthy controls to determine which cell subset 
best demonstrates disease- associated change in IFN response. 
Using all discovery cohort data, tetherin protein levels were com-
pared between the different cell subsets in SLE patients and 
healthy controls by flow cytometry (Table 1).
Tetherin levels differed significantly between cell subsets 
within the group of SLE patients and were highest in monocytes. 
Tetherin levels in T cells were 20% of the levels in monocytes, and 
tetherin levels in plasmablasts were 78% of the levels in mono-
cytes (both P < 0.001). A comparison of the SLE and healthy 
control groups showed that monocyte tetherin MFI in SLE patients 
did not differ significantly from that in healthy controls (SLE:healthy 
control ratio 1.19; P = 0.293), whereas a significantly higher level 
of tetherin was seen in all other subsets in SLE patients ver-
sus healthy controls (ratios 1.37–1.57; all P < 0.05). When the 
between- group ratio for each of the other cell subsets was com-
pared to that for monocytes, the greatest difference was seen 
for memory B cell tetherin levels, which were increased in SLE 
patients (P = 0.046).
Rituximab treatment could confound accurate measurement 
of the B cell phenotype in the SLE patients. We therefore repeated 
these analyses in rituximab- naive patients (Table 1). In rituximab- 
naive patients (n = 76), the largest disease- associated increases in 
tetherin expression versus healthy controls were seen for naive B 
cells (ratio 1.53) and memory B cells (ratio 1.47). These ratios for 
naive and memory B cells were significantly different from that for 
monocytes (P = 0.006 and P = 0.013, respectively). These results 
indicate that differences in IFN response between cell subsets at 
the protein level are clinically relevant, and that B cell tetherin is the 
most clinically relevant parameter.
Tetherin and IFN gene expression assays. Overall 
comparisons of tetherin levels measured on memory B cells and 
2 validated IFN gene expression scores are shown in Supplemen-
tary Figures 3 and 4, available on the Arthritis & Rheumatology 
web site at http://onlin elibr ary.wiley.com/doi/10.1002/art.41187/ 
abstract. As expected, given the difference in cell populations 
analyzed, there was a significant correlation but a degree of 
 disagreement between these assays.
Figure 2. Performance of the tetherin interferon (IFN) flow cytometry assay in discriminating patients based on diagnosis. Age- adjusted 
differences in tetherin levels on the indicated cell subsets between patients with systemic lupus erythematosus (SLE), patients with active 
rheumatoid arthritis (RA) (with a Disease Activity Score in 28 joints of >3.2), and healthy controls (HCs) are shown. Cell surface bone marrow 
stromal antigen 2/tetherin protein levels were determined by flow cytometry of peripheral blood mononuclear cells. Effect sizes (partial η2) 
indicate the degree to which variables differed between groups. We considered an effect size of ≤0.01 to be small, ~0.06 to be medium, and 
≥0.14 to be large (31). Bars show the mean and 90% confidence interval (90% CI). NK = natural killer. Color figure can be viewed in the online 
issue, which is available at http://onlinelibrary.wiley.com/doi/10.1002/art.41187/abstract.
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Clinical validation of the tetherin IFN assay: di-
agnosis. We evaluated the performance of the tetherin flow 
 cytometry assay in distinguishing between patients diagnosed 
as having SLE, those diagnosed as having active RA, and healthy 
controls. Given our previous results, for this analysis we included 
only rituximab- naive patients controlled for age (Figure 2). The 
full statistical table is shown in Supplementary Table 2, available 
on the Arthritis & Rheumatology web site at http://onlin elibr ary.
wiley.com/doi/10.1002/art.41187/ abstract. An effect size of 
≤0.01 was considered small, ~0.06 medium, and ≥0.14 large, 
as described by Cohen (31). Tetherin data revealed a marked 
difference between cell subsets. Monocyte tetherin levels did 
not differentiate SLE patients from healthy controls at all, with 
a ratio of 1.19 (90% CI 0.87–1.61) and an effect size of 0.01. 
T cells and NK cells had moderate effect sizes of 0.06 each. 
However, naive and memory B cell subsets had medium to large 
effect sizes of 0.11, with ratios of 1.63 (90% CI 1.26–2.11) and 
1.59 (90% CI 1.21–2.09), respectively. For memory B cells, the 
SLE:healthy control effect size was 0.11 (P = 0.003), and the 
SLE:RA effect size was 0.17 (P < 0.001).
Tetherin levels differentiated SLE from other inflammatory dis-
ease when compared to active RA. Monocyte tetherin levels had 
no diagnostic function, with a ratio of 1.37 (90% CI 1.00–1.88) 
and an effect size of 0.03. However, all other cell subsets had 
large effect sizes, ranging from 0.14 to 0.23, the effect size for 
plasmablasts (ratio 2.20 [90% CI 1.66–2.93]).
Clinical validation of IFN assays: disease activity 
and autoantibodies. For disease activity, we investigated 
the association between the number of active organ systems 
(BILAG domains scored A, B, or C) per patient compared to 
tetherin levels on cell subsets as well as our recently described 
IFN score A, which comprises 12 type I IFN–selective ISGs 
(7). We controlled for age in all SLE patients (164 observations 
in 124 patients). The number of active domains was categorized 
as 0 (n = 22), 1 (n = 54), 2 (n = 57), or ≥3 (n = 31).
At the 10% level of significance, disease activity was asso-
ciated with IFN score A (R2 = 0.08, P = 0.027) and tetherin 
surface expression on T cells (R2 = 0.07, P = 0.007), NK cells 
(R2 = 0.09, P = 0.001), memory B cells (R2 = 0.09, P = 0.006), and 
plasmablasts (R2 = 0.06, P = 0.020). The degree of association 
was weaker, and hence not significant, for monocytes (R2 = 0.04, 
P = 0.179) and naive B cells (R2 = 0.04, P = 0.103).
For IFN score A, the relationship with disease activity was 
not linear. The only significant association between the score 
and disease activity was attributable to patients with the most 
severely active disease (≥3 domains). A similar, although not sig-
nificant, pattern was observed for monocyte tetherin levels. In 
contrast, there was a linear relationship between memory B cell 
tetherin levels and disease activity, with a stepwise increase in 
tetherin expression for each increase in the number of active 
domains  (Figure  3A). We did not expect a strong correlation 
between memory B cell tetherin levels and IFN score in unsorted 
PBMCs. Since memory B cells are only ~2% of PBMCs, these 
assays do not measure the same biologic effect. We found a 
moderate correlation (Spearman’s R = 0.356, P < 0.0001) 
(Supplementary Figure 3, available on the Arthritis & Rheuma-
tology web site at http://onlin elibr ary.wiley.com/doi/10.1002/
art.41187/ abstract).
To investigate whether the difference between IFN assays 
was due to the type of organ system affected, we analyzed the 2 
most commonly affected domains (mucocutaneous and muscu-
loskeletal) in combination, excluding patients with activity (BILAG 
scores of A, B, or C) in any of the other domains. Although there 
was a significant relationship between each IFN assay and overall 
disease activity, the relationship with IFN assays varied between 
these 2 organ systems (Figure 3B). For IFN score A, increased 
expression was only seen with mucocutaneous disease activity. 
For monocyte tetherin levels, increases were observed only in 
patients with musculoskeletal disease activity. This finding may 
explain why this assay does not show a linear relationship with 
disease activity. However, memory B cell tetherin had a more 
consistent relationship with disease activity in both organ sys-
tems. Tetherin levels were lowest in patients in clinical remission, 
higher in patients with active disease in a single organ, and high-
est in patients with active disease in both organs.
The numbers of patients with other active organ domains 
were more limited. Of patients with no activity in other domains, 12 
had active hematologic disease (BILAG score of A or B) (immune- 
mediated hemolysis or thrombocytopenia). Memory B cell teth-
erin MFI in the patients with active hematologic disease versus 
those with inactive disease was 1,954 versus 1,494, respectively 
(P = 0.005). Eight patients had active renal disease. Comparing 
these 8 patients with active renal disease to patients with inac-
tive disease also revealed a significant increase in memory B cell 
tetherin levels (MFI 2,625 versus 1,562; P = 0.005). Tetherin levels 
were not associated with glucocorticoid use (Supplementary 
Figure 5, available on the Arthritis & Rheumatology web site at 
http://onlin elibr ary.wiley.com/doi/10.1002/art.41187/ abstract). 
In our rituximab- naive patients, there was a positive correlation 
between memory B cell tetherin expression and autoantibodies 
summarized as the number of extractable nuclear antigen sub-
types (R = 0.412, P = 0.0001) (Supplementary Figure 6, available 
on the Arthritis & Rheumatology web site at http://onlin elibr ary.
wiley.com/doi/10.1002/art.41187/ abstract).
For additional comparison to alternative IFN assays, we 
classified patients as type I IFN positive or type I IFN negative 
according to a 5- gene IFN signature, as described by Higgs et al 
(32). Results are shown in Supplementary Figure 7, available on 
the Arthritis & Rheumatology web site at http://onlin elibr ary.wiley.
com/doi/10.1002/art.41187/ abstract. The majority of the SLE 
patients were in the type I IFN–positive subgroup. As expected, 
this subgroup had worse BILAG disease activity (P = 0.016). To 
determine whether tetherin expression gave additional informa-
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tion in comparison to the gene expression status, we retested the 
association of tetherin levels with BILAG scores within the type 
I IFN–positive subgroup. We still found a significant association 
between tetherin expression and disease activity (Spearman’s R = 
0.321, P = 0.038), which could not be measured using the more 
standard assay. This finding indicates that memory B cell tetherin 
Figure 3. Association between interferon (IFN) assays and disease activity in systemic lupus erythematosus (SLE). A, Association between 
different IFN assays (IFN score A, monocyte tetherin levels, and memory B cell tetherin levels) and the number of organ systems (domains) with 
active disease in the discovery cohort (164 observations in 124 SLE patients). IFN score A was increased in patients with ≥3 active domains, 
but not in patients with 1 or 2 active domains, compared to those with 0 active domains (remission). Tetherin mean fluorescence intensity (MFI) 
measured on memory B cells demonstrated a more consistent stepwise increase with increasing disease activity. Bars show the mean and 
90% confidence interval (90% CI), calculated using the 2−ΔCt method (i.e., taller bars represent higher expression). Broken lines and shaded 
areas represent the mean and 90% CI in healthy controls (HCs; n = 23). B, Association between different IFN assays and musculoskeletal 
and mucocutaneous disease activity. Disease activity was defined as active (British Isles Lupus Assessment Group [BILAG] score of A or B) 
or inactive (BILAG score of D or E). Patients with activity in other organs were excluded. For IFN score A, there were inconsistent relationships 
with disease activity, with an increase with skin involvement, but not musculoskeletal involvement alone. For monocyte tetherin levels, increased 
protein expression was seen with musculoskeletal disease activity but not with skin activity alone. Tetherin levels measured on memory B cells 
demonstrated a consistent relationship with both common types of clinical disease. Bars show the median. C, Association between different 
IFN assays (monocyte tetherin levels and memory B cell tetherin levels) and the number of organ systems with active disease in the validation 
cohort. Results were similar to those for the discovery cohort, shown in A. Bars show the mean ± SD (n = 80 patients). D, Scatterplots showing 
association between overall disease activity (BILAG global score) and tetherin levels. There was a significant association between BILAG global 
score and memory B cell tetherin levels but not monocyte tetherin levels. E, Relationship between tetherin levels and SLE disease flare. Memory 
B cell tetherin levels were significantly predictive of subsequent clinical flare (hazard ratio [HR] 2.290 [95% CI 1.013–4.644]; P = 0.022), while 
monocyte tetherin levels were not (HR 0.814 [95% CI 0.580–1.141]; P = 0.231).
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gives additional clinically relevant information compared to the IFN 
signature alone.
Clinical validation of IFN assays: plasmablasts. Last, 
in the discovery cohort, we used the plasmablast count to 
represent current B cell activity and differentiation. Type I IFN 
is known to promote the differentiation of memory B cells into 
plasmablasts (33). We have previously shown that an early rapid 
population of plasmablasts after rituximab treatment led to an 
early clinical relapse (19,34). We hypothesized that the mem-
ory B cell tetherin level would correlate with circulating plasma-
blast numbers after rituximab treatment, reflecting an increased 
rate of differentiation secondary to type I IFN. The results are 
shown in Table 2. In rituximab- naive patients, no relationship was 
found between any tetherin IFN assay and plasmablast count. 
In patients who had received rituximab treatment there was no 
correlation between monocyte, NK, or T cell tetherin levels and 
plasmablast numbers, but memory B cell tetherin levels were 
significantly correlated with plasmablast numbers (Spearman’s 
R = 0.38, P = 0.047) as well as inversely correlated with time to 
clinical relapse (R = 0.623, P = 0.022). To further explore whether 
tetherin surface protein expression was associated with the 
induction of relevant pathogenic pathways in B cells, we evalu-
ated 2 transcripts for downstream plasmablast function: IgJ for 
antibody synthesis in all samples, and ISG15 for ISG- 15 protein 
secretion in sorted memory B cells. Both of these transcripts 
showed a significant correlation with flow cytometric measure-
ment of memory B cell tetherin MFI (Supplementary Figure 8, 
available on the Arthritis & Rheumatology web site at http://
onlinelibrary.wiley.com/doi/10.1002/art.41187/abstract).
Independent validation cohort. The independent val-
idation cohort consisted of an additional 80 patients with SLE 
who were recruited and studied prospectively. Memory B cell and 
monocyte tetherin levels were measured using fresh lysed whole 
blood in an independent accredited diagnostic laboratory. Disease 
activity was measured at the time of sampling using the BILAG 
2004. Patients were followed up for subsequent flare (a BILAG 
score of A or B).
We found a similar relationship between tetherin levels and 
disease activity as in our discovery cohort. There was a significant 
relationship between the number of organ domains with active 
disease and memory B cell tetherin levels (P = 0.0005) but no rela-
tionship with monocyte tetherin levels (P = 0.759) (Figure 3C). There 
was a significant association between global BILAG score and 
memory B cell tetherin levels (Spearman’s R = 0.503, P < 0.0001) 
but no association with monocyte tetherin levels (R = 0.058, 
P = 0.627) (Figure  3D). Additionally, in this cohort we demon-
strated that in patients in clinical remission at the time of sampling 
(n = 36), memory B cell tetherin levels predicted time to clinical 
flare. In a multivariable Cox regression analysis including mem-
ory B cell tetherin level, monocyte tetherin level, and age, mem-
ory B cell tetherin level was a significant predictor of subsequent 
BILAG A/B flare (hazard ratio [HR] 2.290 [95% CI 1.013–4.644]; 
P = 0.022). Monocyte tetherin level did not significantly predict 
flare (HR 0.814 [95% CI 0.580–1.141]; P = 0.231) (Figure 3E). In 
conclusion, we independently confirmed that disease activity is 
related to type I IFN response in memory B cells measured using 
tetherin, and further, that this is predictive of clinical outcome.
DISCUSSION
In this study we demonstrated the value of a novel cell- specific 
biomarker based on the IFN- inducible protein tetherin, using in 
vitro methods and human clinical studies. We showed that flow 
cytometric measurement of memory B cell surface tetherin lev-
els captured cell- specific type I IFN response, was responsive to 
increasing doses of type I IFN, and had a strong and consistent 
relationship with disease activity, B cell activity, and time to flare in 
2 cohorts of SLE patients. These results are important because 
type I IFN and B cells play a role in many autoimmune diseases, 
and their measurement has the potential to stratify outcomes and 
use of therapies, though previous studies have yielded conflicting 
results (35).
Better biomarkers are needed in SLE. European League 
Against Rheumatism treat- to- target recommendations advise 
treating to a target of low disease activity, while minimizing expo-
sure to glucocorticoids (36). Predictors of a severe disease tra-
jectory or flares are needed to achieve this goal. Response to 
conventional and targeted therapies in SLE and related diseases 
is variable, and reclassification of autoimmune diseases according 
to pathogenic mechanisms instead of clinical features has been 
proposed (35).
The crucial role of type I IFN in the pathogenesis of SLE and 
related diseases is indicated by genetic susceptibility and mono-
genic interferonopathies as well as evidence of overexpression 
(35). As such, it has face validity as a stratification biomarker. 
Table  2. Association between candidate IFN assays and 
plasmablast level following B cell depletion therapy in SLE patients*
Plasmablast count 
before rituximab 
treatment 
(n = 50)
Plasmablast count 
after rituximab 
treatment 
(n = 28)
IFN score A –0.11 0.24
Tetherin protein level
Monocytes –0.08 0.20
T cells –0.16 0.32
NK cells –0.14 0.05
Naive B cells –0.04 0.30
Memory B cells 0.07 0.38†
* Values are Spearman’s rank correlation coefficient. Interferon (IFN) 
score A was measured on unsorted peripheral blood mononuclear 
cells, and tetherin mean fluorescence intensity (MFI) on each cell 
subset was analyzed by flow cytometry. SLE = systemic lupus 
erythematosus; NK = natural killer. 
† P = 0.047 for correlation between plasmablast count and tetherin MFI. 
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Existing studies indicate the potential value of measuring type I 
IFN for diagnosis and prediction of flares. Type I IFN biomarkers 
may also predict clinical response to tumor necrosis factor block-
ade, B cell depletion, and type I IFN blockade in RA and SLE (35).
Nevertheless, there are limitations to previous approaches 
to measuring type I IFN activity, and some previous results have 
been contradictory. Direct measurement of type I IFN protein is 
limited by the number of different ligands and instability in serum, 
with most cell types expressing the type I IFN receptor. A recent 
improvement was the use of single- molecule arrays (Simoa). The 
higher sensitivity of Simoa allows for reliable measurement of 
IFNα (6). However, this assay is currently expensive and limited in 
availability and has not been validated against clinical outcomes. 
For ISG expression–based methods, another issue is the effect 
of other IFN subtypes or other inflammatory mediators. ISGs are 
known to fall into distinct subsets, which may be due to the effect 
of type II IFN (7,9). We previously showed that there are different 
patterns of ISG expression in different autoimmune diseases. In 
the present study we confirmed that tetherin is selectively respon-
sive to type I IFN, and we included ANA- negative RA patients as 
inflammatory disease controls. (We did not see any elevation of 
tetherin levels in our RA patients as others have reported for an 
IFN signature, but this difference may be due to our selection of 
only ANA- negative cases rather than differences in the biomarkers).
While candidate biomarker discoveries in autoimmunity are 
numerous, a significant challenge is validation in clinically relevant 
contexts (37). An important aspect of our work is the degree of 
preclinical and clinical validation. We used 2 methods of validation 
to demonstrate that tetherin reflects cellular response to type I 
IFN. We demonstrated a correlation with existing validated IFN 
assays. However, such concurrent validity studies are limited by 
the potential imprecision of the IFN scores. These scores may 
be affected by changes in the cellular composition of the sam-
ple or other subtypes of IFNs. Moreover, tetherin assesses the 
response to IFN of a specific cell subset (we have shown memory 
B cells), while IFN scores assess a mixed population of cells and 
will be influenced by other cell types. For these reasons, the more 
important method of demonstrating that tetherin reflects cellular 
response to type I IFN is through in vitro stimulation assays. We 
showed that tetherin has a dose- dependent response to type I 
IFN in multiple cell subsets, far exceeding response to type II IFN. 
Our data therefore demonstrate good face and construct valid-
ity, as well as concurrent and prospective criterion validation and 
feasibility in a routine clinical setting. We also present validation 
against a range of different clinical and longitudinal end points.
Cell- specific measurement based on flow cytometry has 
been demonstrated previously using expression of Siglec- 1, 
another cell surface protein convenient for flow cytometry that 
is expressed by monocytes. Monocyte Siglec- 1 expression has 
been shown to correlate with disease activity as well as predict 
autoimmune congenital heart block (25,38,39). This was a sig-
nificant advance in analysis of IFN status. In the present study 
we advanced this principle further by using a marker expressed 
on all circulating cells. Tetherin captures the same information as 
Siglec- 1 on monocytes, but also evaluates other cell subsets. We 
have shown that results from these different subsets vary, with the 
strongest clinical correlation for memory B cells. This method has 
distinct advantages when there is particular interest in a specific 
cell population, such as with the B cell–directed therapies rituxi-
mab and belimumab in SLE. B cell response to type I IFN is crucial 
in SLE.
While there were many associations between tetherin protein 
expression and clinical features of SLE, memory B cell tetherin 
levels seemed to be particularly important. This marker correlated 
best with clinical features, and was the only marker to be asso-
ciated with plasmablast number. After B cell depletion with ritux-
imab, there is a highly variable rate of plasmablast repopulation 
that predicts clinical relapse. Understanding the determinants of 
these repopulation patterns may reveal upstream factors con-
trolling B cell autoreactivity. One previous study showed a relation-
ship between serum BAFF titers and the numbers of plasmablasts 
at relapse (40). However, BAFF may not be the only factor. Type 
I IFN also promotes B cell activation and differentiation into plas-
mablasts and plasma cells (28,41). This may include direct influ-
ences; for example, in animal models type I IFN influences B cell 
receptor– and Toll- like receptor–mediated response to self nuclear 
antigen. Our work provides data from human disease to support 
this observation (42,43). Additionally, type I IFN induces a plasma 
cell phenotype that secretes ISG- 15 with additional proinflamma-
tory effects (17). In the present study, we found that memory B cell 
tetherin levels correlated with plasmablast expansion after rituxi-
mab treatment. A plasmablast signature was recently shown to be 
a strong biomarker for SLE, and we and others previously showed 
that plasmablast expansion after rituximab was strongly predic-
tive of clinical relapse (19,44,45). This was further supported by a 
correlation between memory B cell tetherin levels and transcripts 
representing disease- relevant B cell dysfunction.
The tetherin biomarker has some limitations. First, although 
this flow cytometry assay avoids confounders that may affect ISG 
expression scores, analyzing a single IFN- inducible transcript may 
be more susceptible to the influence of other inflammatory stimuli, 
which we cannot exclude based on these results. However, our 
data comparing SLE to the RA disease control are very consist-
ent with those we observed using IFN scores, with a clear differ-
ence in IFN score A and tetherin expression between SLE and 
RA. Tetherin, like all type I IFN biomarkers, may be influenced by 
acute or chronic viral infections, which were excluded from this 
study. It may be more difficult to perform flow cytometry in some 
situations. However, with widespread use of flow cytometry in cell- 
targeted therapies in autoimmunity and oncology, as well as in 
routine monitoring of HIV, addition of tetherin cell surface staining 
is a highly cost- effective test. Tetherin may be analyzed in combi-
nation with B cell and plasmablast flow cytometry to stratify both 
B cell– and type I IFN–blocking therapy.
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In summary, we describe measurement of the IFN- inducible 
protein tetherin on B cells as a cell- specific biomarker with a num-
ber of advantages and widespread applications in clinical and 
laboratory research in this rapidly expanding area of immunology.
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